Compare ACRS & HDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | HDL |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 723.1M |
| IPO Year | 2015 | 2023 |
| Metric | ACRS | HDL |
|---|---|---|
| Price | $6.28 | $14.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $10.20 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 858.0 |
| Earning Date | 05-07-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | $14.73 |
| Revenue Next Year | $4.24 | $12.94 |
| P/E Ratio | ★ N/A | $55.56 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.74 | $12.00 |
| 52 Week High | $6.52 | $21.21 |
| Indicator | ACRS | HDL |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 60.45 |
| Support Level | $4.13 | $13.07 |
| Resistance Level | $6.52 | $15.40 |
| Average True Range (ATR) | 0.36 | 0.12 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 83.72 | 100.00 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.